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IntroductIon
After the first reports of patients with AIDS 
in 1981, the discovery in 1983 of HIV as 
the etiological agent that causes AIDS and 
in 1984 of the CD4 protein as the main 
receptor for the virus our views on HIV 
pathology have been quite straightforward. 
Apparently HIV infects CD4+ human 
cells, which are mainly T helper cells, and 
in vitro studies show that these cells die 
in the course of a productive HIV infec-
tion. Thus, HIV is cytopathic for CD4+ T 
helper cells and this relates directly to very 
low CD4+ T helper cells in patients that 
present with AIDS symptoms and to the 
progressive loss of these cells in the course 
of HIV infection to AIDS. Indeed, in HIV 
infection the degree of depletion of CD4+ 
T cell numbers is since these days used as 
the main marker of disease progression 
(Fauci et al., 1996). This cytopathic model 
of AIDS pathogenesis has been boosted by 
two additional observations of very differ-
ent kinds. First, Ho et al. (1995) showed 
the true viral dynamics of HIV infection, 
making it clear that even in asymptomatic 
individuals daily production of HIV is very 
high, at least in the order of 10 (Grossman 
et al., 2002) viral particles per day, with a 
RT error rate that creates HIV tremendous 
variation and allows for rapid escape from 
drug and immune pressure. In addition, 
these authors reported high CD4+ T cell 
death rates and compensatory production 
of these cells which exhausts the immune 
system eventually depleting CD4+ T cells, 
the cause of AIDS. Second, in 1996 formal 
molecular proof was reported for two dis-
tinct co-receptors of HIV (Cocchi et al., 
1995; Feng et al., 1996) that explained the 
observation of HIV variants with different 
cytopathicity and with different cellular 
tropism (Tersmette et al., 1989; Koot et al., 
1993; Connor et al., 1997). Although in 
both immunology and virology there were 
problems regarding this cytopathic account 
of HIV/AIDS, not in the least because of the 
lack of a better comprehensive model, until 
very recently it has been the dominant view 
in textbooks and the literature.
chronIc InflammatIon drIves hIv 
assocIated dIsease
Our insights and ideas about AIDS patho-
genesis have gradually but drastically 
changed over the past decade and it is now 
widely held that the direct cytopathic effects 
of HIV do not, but the chronic inflammation 
that HIV induces does explain progression 
to AIDS (Hazenberg et al., 2000; McCune, 
2001; Grossman et al., 2002; Douek et al., 
2003). This is based on the fact that pro-
gression to disease is better predicted by the 
level of immune activation. Various mark-
ers of adaptive and innate immune activa-
tion are better and independent prognostic 
markers than CD4+ T cell numbers and 
viral load (Fahey et al., 1990; Giorgi et al., 
1999; Hazenberg et al., 2003; Deeks et al., 
2004). Furthermore, SIV monkey models 
strongly suggest that, even in the presence of 
high viral loads of cytopathic SIV, without 
chronic immune activation progression to 
disease is not observed, which corresponds 
to the rare non-progressing patients that 
have high viral loads (Silvestri et al., 2003). 
This has led to a view on HIV pathogenesis 
that is quite different from the classical cyto-
pathic model and which has implications 
for therapy and vaccine development. The 
recent finding that inflammation in non-
pathogenic SIV infection is actively down 
regulated by a gene expression program that 
is activated early after acute SIV infection 
prompts investigation into the mechanisms 
of that inhibitory gene expression and how 
it is started (Bosinger et al., 2009). In anal-
ogy, it will be key to understand why in 
humans in practically no infected individ-
ual an efficient and inhibitory gene expres-
sion profile is activated.
A first important insight from this devel-
opment is that in HIV infection, immune 
deficiency is the result of chronic activation 
of both the adaptive and innate immune 
system and is not an immediate effect of 
HIV infection. HIV induces activation of 
virtually all leukocyte populations (Deeks, 
2011) and in agreement with that in asymp-
tomatic but even in late stage HIV infec-
tion strong cellular and humoral immune 
responses are mounted from which the 
virus escapes, already in the first weeks 
after HIV infection, irrespective of the 
HLA background of the host, the virus is 
under severe pressure of cytotoxic T lym-
phocytes (CTL; Goonetilleke et al., 2009; 
Fischer et al., 2010). Leukocyte activation 
is reflected in activated cells, expression, 
and massive release of pro-inflammatory 
cytokines. Evidence for adaptive response 
has been complemented by our more recent 
insights that HIV single stranded (ss) RNA 
directly activates the innate immune sys-
tem via Toll like receptor (TLR) 7 and 8 in 
pDC and macrophages which causes the 
release of TNF alpha (Beignon et al., 2005; 
Meier et al., 2007). This has down-stream 
activating effects on NK, B cells, and CD4+ 
and CD8+ T cell and their turnover (Hardy 
et al., 2007). In addition, bacterial products, 
including LPS and peptidoglycans, translo-
cating from the gut are implied in driving 
immune activation even further. Bacterial 
translocation results from HIV associated 
depletion of CD4+ T cells from gut mucosa 
which affects gut integrity important to 
contain microbes in the GI tract (Brenchley 
et al., 2006). Further investigation to under-
stand the contribution of bacterial translo-
cation to immune activation is warranted.
non-aIds dIsease assocIated wIth 
hIv InfectIon
It is recognized that chronic inflamma-
tion underlies pathology in various clini-
cal conditions, obviously in autoimmune 
diseases, IBD, and Crohn’s disease, but also 
in atherosclerosis and cardiovascular dis-
ease (CVD), some neurological diseases 
and liver and kidney failure (Medzhitov, 
2010). Although initially cardiovascular, 
liver, and kidney disease was believed to be 
associated with side effects of some anti-
viral drugs, more recently HIV induced 
inflammation is thought to be implied also 
in these non-AIDS diseases (Bozzette et al., 
2003; El-Sadr et al., 2006). Although cART 
diminishes viral load and through that takes 
away most of the driver of inflammation, 
patients on long term cART have increased 
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Since the STEP trial was stopped in 2007 
because of a lack of effect on viral set point 
in vaccines after break through infection, 
vaccine development has been reevaluated. 
The concept of CTL based vaccines has been 
seriously questioned since it will not pro-
vide protection from infection and only 
temporarily slow down disease progres-
sion. Still, the idea of a CTL based vaccine 
has not been abandoned and encouraging 
and surprising results using a CMV based 
viral vector have just been reported in the 
SIV monkey model (Hansen et al., 2011). 
The field has at the same time seen a swing 
back to NeuAb and vaccine design based on 
the epitopes of broadly and potently NeuAb 
has been fueled by interesting novel NeuAb 
specificities that were recently reported (Wu 
et al., 2010; Zhou et al., 2010).
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therapy
cART is effectively used for more than 
15 years now and novel drugs targeting 
viral fusion are being developed and used. 
A serious problem is viral escape from anti-
virals and the transmission of drug-resistant 
variants, in developed and even more in 
developing countries were cART has been 
administered. Immune therapy by therapeu-
tic vaccination has not been successful and 
may be questioned as we now realize that 
immune activation is detrimental and spe-
cific immune response are strong (Autran 
et al., 2008). It could be that the quality of 
CTL and neutralizing antibodies (NeuAb) 
which prevail in chronic infection may be 
insufficient for control of HIV which may 
be eligible for restoration and enhancement 
(Betts et al., 2006). Similarly, immune ther-
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as TNF alpha and other inflammation path-
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with non-AIDS end organ diseases. Novel 
genetic analyses using large data sets, more 
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matics tools may help to define novel targets 
for therapeutic intervention in the immune 
system that are critical for disease progres-
sion or control of inflammation in HIV 
infected individuals. Finally it still remains 
the question whether the virus can be eradi-
cated from an infected host and what type of 
therapy would be required for that.
hIv specIfIc ImmunIty and hIv 
vaccInes
HIV can effectively escape from CTL and 
NeuAb. Some CTL that are restricted by rare 
protective HLA, mainly B57, have been asso-
ciated with a lower viral load set point that 
may be caused by CTL driven viral attenua-
tion (Leslie and Goulder, 2006; Frater et al., 
2007; Navis et al., 2007; Miura et al., 2010). 
Despite these effects, CTL do not appear to 
protect from disease progression (Schellens 
et al., 2008). Similarly, NeuAb drive escape 
Frontiers in Immunology | HIV and AIDS  September 2011 | Volume 2 | Article 20 | 2
Miedema Immunology of HIV and AIDS
Sereti, I., Dunham, R. M., Spritzler, J., Aga, E., Proschan, 
M. A., Medvik, K., Battaglia, C. A., Landay, A. L., 
Pahwa, S., Fischl, M. A., Asmuth, D. M., Tenorio, A. R., 
Altman, J. D., Fox, L., Moir, S., Malaspina, A., Morre, 
M., Buffet, R., Silvestri, G., and Lederman, M. M., 
ACTG 5214 Study Team. (2009). IL-7 administra-
tion drives T cell-cycle entry and expansion in HIV-1 
infection. Blood 113, 6304–6314.
Silvestri, G., Sodora, D. L., Koup, R. A., Paiardini, M., 
O’Neil, S. P., McClure, H. M., Staprans, S. I., and 
Feinberg, M. B. (2003). Nonpathogenic SIV infec-
tion of sooty mangabeys is characterized by limited 
bystander immunopathology despite chronic high-
level viremia. Immunity 18, 441–452.
Tersmette, M., Gruters, R. A., de Wolf, F., de Goede, R. E., 
Lange, J. M., Schellekens, P. T., Goudsmit, J., Huisman, 
H. G., and Miedema, F. (1989). Evidence for a role 
of virulent human immunodeficiency virus (HIV) 
variants in the pathogenesis of acquired immunode-
ficiency syndrome: studies on sequential HIV isolates. 
J. Virol. 63, 2118–2125.
Wu, X., Yang, Z. Y., Li, Y., Hogerkorp, C. M., Schief, W. 
R., Seaman, M. S., Zhou, T., Schmidt, S. D., Wu, L., 
Xu, L., Longo, N. S., McKee, K., O’Dell, S., Louder, M. 
K., Wycuff, D. L., Feng, Y., Nason, M., Doria-Rose, N., 
Connors, M., Kwong, P. D., Roederer, M., Wyatt, R. T., 
Nabel, G. J., and Mascola, J. R. (2010). Rational design 
of envelope identifies broadly neutralizing human 
monoclonal antibodies to HIV-1. Science 329, 856–861.
Zhou, T., Georgiev, I., Wu, X., Yang, Z. Y., Dai, K., Finzi, 
A., Kwon, Y. D., Scheid, J. F., Shi, W., Xu, L., Yang, Y., 
Zhu, J., Nussenzweig, M. C., Sodroski, J., Shapiro, L., 
Nabel, G. J., Mascola, J. R., and Kwong, P. D. (2010). 
Structural basis for broad and potent neutralization 
of HIV-1 by antibody VRC01. Science 329, 811–817.
Received: 23 May 2011; accepted: 25 May 2011; published 
online: 23 September 2011.
Citation: Miedema F (2011) Grand Challenges in the 
immunology of HIV and AIDS. Front. Immun. 2:20. doi: 
10.3389/fimmu.2011.00020
This article was submitted to Frontiers in HIV and AIDS, 
a specialty of Frontiers in Immunology.
Copyright © 2011 Miedema. This is an open-access article 
subject to a non-exclusive license between the authors and 
Frontiers Media SA, which permits use, distribution and 
reproduction in other forums, provided the original authors 
and source are credited and other Frontiers conditions are 
complied with.
turnover of plasma virions and CD4+ lymphocytes 
in HIV-1 infection. Nature 373, 123–126.
Jiang, W., Lederman, M. M., Hunt, P., Sieg, S. F., Haley, 
K., Rodriguez, B., Landay, A., Martin, J., Sinclair, 
E., Asher, A. I., Deeks, S. G., Douek, D. C., and 
Brenchley, J. M. (2009). Plasma levels of bacterial 
DNA correlate with immune activation and the 
magnitude of immune restoration in persons with 
antiretroviral-treated HIV infection. J. Infect. Dis. 
199, 1177–1185.
Koot, M., Keet, I. P., Vos, A. H., de Goede, R. E., Roos, M. 
T., Coutinho, R. A., Miedema, F., Schellekens, P. T., 
and Tersmette, M. (1993). Prognostic value of human 
immunodeficiency virus type 1 biological phenotype 
for rate of CD4+ cell depletion and progression to 
AIDS. Ann. Intern. Med. 118, 681–688.
Leslie, A. J., and Goulder, P. J. (2006). HIV escape and 
attenuation by cytotoxic T lymphocytes. Curr. Opin. 
HIV AIDS 1, 34–39.
McCune, J. M. (2001). The dynamics of CD4+ T-cell 
depletion in HIV disease. Nature 410, 974–979.
Medzhitov, R. (2010). Inflammation 2010: new adven-
tures of an old flame. Cell 140, 771–776.
Meier, A., Alter, G., Frahm, N., Sidhu, H., Li, B., Bagchi, 
A., Teigen, N., Streeck, H., Stellbrink, H. J., Hellman, 
J., van Lunzen, J., and Altfeld, M. (2007). MyD88-
dependent immune activation mediated by human 
immunodeficiency virus type 1-encoded Toll-like 
receptor ligands. J. Virol. 81, 8180–8191.
Miura, T., Brumme, Z. L., Brockman, M. A., Rosato, 
P., Sela, J., Brumme, C. J., Pereyra, F., Kaufmann, D. 
E., Trocha, A., Block, B. L., Daar, E. S., Connick, E., 
Jessen, H., Kelleher, A. D., Rosenberg, E., Markowitz, 
M., Schafer, K., Vaida, F., Iwamoto, A., Little, S., and 
Walker, BD. (2010). Impaired replication capacity 
of acute/early viruses in persons who become HIV 
controllers. J. Virol. 84, 7581–7591.
Navis, M., Schellens, I., van Baarle, D., Borghans, J., 
van Swieten, P., Miedema, F., Kootstra, N., and 
Schuitemaker, H. (2007). Viral replication capac-
ity as a correlate of HLA B57/B5801-associated 
nonprogressive HIV-1 infection. J. Immunol. 179, 
3133–3143.
Schellens, I. M., Borghans, J. A., Jansen, C. A., De Cuyper, 
I. M., Geskus, R. B., van Baarle, D., and Miedema, F. 
(2008). Abundance of early functional HIV-specific 
CD8+ T cells does not predict AIDS-free survival 
time. PLoS ONE 3, e2745. doi: 10.1371/journal.
pone.0002745
immunodeficiency virus mutants and slow disease 
progression. J. Virol. 81, 6742–6751.
Giorgi, J. V., Hultin, L. E., McKeating, J. A., Johnson, 
T. D., Owens, B., Jacobson, L. P., Shih, R., Lewis, J., 
Wiley, D. J., Phair, J. P., Wolinsky, S. M., and Detels, 
R. (1999). Shorter survival in advanced uman immu-
nodeficiency virus type 1 infection is more closely 
associated with T lymphocyte activation than with 
plasma virus burden or virus chemokine coreceptor 
usage. J. Infect. Dis. 179, 859–870.
Goonetilleke, N., Liu, M. K., Salazar-Gonzalez, J. F., 
Ferrari, G., Giorgi, E., Ganusov, V. V., Keele, B. F., 
Learn, G. H., Turnbull, E. L., Salazar, M. G., Weinhold, 
K. J., Moore, S., CHAVI Clinical Core B, Letvin, N., 
Haynes, B. F., Cohen, M. S., Hraber, P., Bhattacharya, 
T., Borrow, P., Perelson, A. S., Hahn, B. H., Shaw, G. M., 
Korber, B. T., and McMichael, A. J. (2009). The first T 
cell response to transmitted/founder virus contributes 
to the control of acute viremia in HIV-1 infection. J. 
Exp. Med. 206, 1253-1272.
Grossman, Z., Meier-Schellersheim, M., Sousa, A. E., 
Victorino, R. M. M., and Paul, W. E. (2002). CD4 
T-cell depletion in HIV infection: are we closer to 
understanding the cause ? Nat. Med. 8, 319–323.
Hansen, S. G. Ford, J. C., Lewis, M. S., Ventura, A. B., 
Hughes, C. M., Coyne-Johnson, L., Whizin, N., 
Oswald, K., Shoemaker, R., Swanson, T., Legasse, A. 
W., Chiuchiolo, M. J., Parks, C. L., Axthelm, M. K., 
Nelson, J. A., Jarvis, M. A., Piatak, M. Jr., Lifson, J. 
D., and Picker, L. J. (2011). Profound early control of 
highly pathogenic SIV by an effector memory T-cell 
vaccine. Nature 473, 523–527.
Hardy, A. W., Graham, D. R., Shearer, G. M., and 
Herbeuval, J. P. (2007). HIV turns plasmacytoid 
dendritic cells (pDC) into TRAIL-expressing killer 
pDC and down-regulates HIV coreceptors by Toll-like 
receptor 7-induced IFN-alpha. Proc. Natl. Acad. Sci. 
U.S.A. 104, 17453–17458.
Hazenberg, M. D., Hamann, D., Schuitemaker, H., and 
Miedema, F. (2000). T cell depletion in HIV-1 infec-
tion: how CD4+ T cells go out of stock. Nat. Immunol. 
1, 285–289.
Hazenberg, M. D., Otto, S. A, van Benthem, B. H., Roos, 
M. T., Coutinho, R. A., Lange, J. M., Hamann, D., Prins, 
M., and Miedema, F. (2003). Persistent immune acti-
vation in HIV-1 infection is associated with progres-
sion to AIDS. AIDS 17, 1881–1888.
Ho, D. D., Neumann, A. U., Perelson, A. S., Chen, W., 
Leonard, J. M., and Markowitz, M. (1995). Rapid 
www.frontiersin.org September 2011 | Volume 2 | Article 20 | 3
Miedema Immunology of HIV and AIDS
